For generalized myasthenia gravis, Klygefa introduces a pioneering therapy combining C5 inhibition effectiveness with the convenience of an autoinjector for weekly subcutaneous self-injection.
AstraZeneca PLC announced that Alexion’s Klygefa treatment received approval in both the US and EU for adults with generalized myasthenia gravis, a rare autoimmune disorder that causes severe muscle weakness, Morningstar reported.
The Cambridge, England-based pharmaceutical company said that the approvals relied on positive results from the phase 3 Prevail trial. The study demonstrated clinical improvement as early as week one compared to a placebo.
Klygefa operates as an inhibitor that binds to the C5 protein in the terminal complement cascade, which forms a part of the body’s immune system. AstraZeneca said that uncoordinated activation of the complement cascade causes it to overreact, prompting the immune system to target healthy tissue.
- Targeted Inhibition: Klygefa binds directly to the C5 protein to block the overactive immune response that destroys healthy muscle tissue in generalized myasthenia gravis patients.
- Extended Half-Life: The treatment features dual-binding nanobody technology that attaches to serum albumin to lengthen its presence in the body, allowing for once-weekly dosing.
- Self-Administration: Patients can self-administer the treatment subcutaneously once weekly via autoinjector.
Marc Dunoyer, chief executive officer at Alexion, AstraZeneca’s rare disease division, commented on the approvals.
“The US approval of Klygefa delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 inhibition with the flexibility of once-weekly subcutaneous self-administration via autoinjector.”
said Marc Dunoyer, chief executive officer at Alexion, AstraZeneca’s rare disease division.
Dunoyer added that the approval in the EU marked an important milestone for the generalized myasthenia gravis community. The Prevail trial evaluated the safety and efficacy of the dual-binding nanobody against a placebo.
Separately, AstraZeneca reported that its cancer treatment Imfinzi won US approval for use in a perioperative regimen alongside enfortumab vedotin for patients with muscle-invasive bladder cancer. That decision followed results from the phase 3 Volga trial.
Following the regulatory announcements, AstraZeneca shares traded 0.4% higher at 14,044.00 pence each on Monday morning in London.
| Treatment | Condition | Key Trial | Primary Efficacy Result |
|---|---|---|---|
| Klygefa | Generalized Myasthenia Gravis | Prevail (Phase 3) | Clinical improvement observed by week one vs. placebo |
| Imfinzi | Muscle-Invasive Bladder Cancer | Volga (Phase 3) | 49% reduction in recurrence risk and 42% reduction in death risk |
The approvals in the US and the EU apply to adults with generalized myasthenia gravis and were based on the positive results from the phase 3 Prevail trial submitted by AstraZeneca.
AstraZeneca said that Klygefa’s concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing, and that the complement cascade, when activated in an uncontrolled manner, over-responds, leading the body to attack its own healthy cells.
- Morningstar. AstraZeneca PLC alliance news coverage and market reports.
- AstraZeneca PLC. Phase 3 Prevail trial clinical data releases.
- AstraZeneca PLC. Phase 3 Volga trial clinical data releases.